Alpha 2.0
Login Register
» Authors » Isabel Prieto-Conde

Isabel Prieto-Conde

Explore the profile of Isabel Prieto-Conde including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 68
Followers 0
Related Specialties
General Medicine
Pathology
Science
Top 10 Co-Authors
Marcos Gonzalez
Ramon Garcia-Sanz
Miguel Alcoceba
Cristina Jimenez
Noemi Puig
Maria Garcia-Alvarez
Alejandro Medina
Veronica Gonzalez-Calle
M Carmen Chillon
Ana Balanzategui
Published In
Blood Cancer J
PLoS One
J Clin Pathol
Arch Pathol Lab Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
Santisteban-Espejo A, Benavides-De la Fuente C, Mangas-Rojas A, Montero-Pavon P, Bernal-Florindo I, Aldaco-Puntas E, et al.
J Clin Pathol . 2025 Jan; PMID: 39837608
Aims: The prognostic impact of B lymphocytes surrounding Hodgkin and Reed Sternberg (HRS) cells in classic Hodgkin lymphoma (cHL) and pathogenic variants in genes associated with apoptosis regulation remains undefined....
2.
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma
Medina A, Jimenez C, Puig N, Sarasquete M, Flores-Montero J, Garcia-Alvarez M, et al.
Arch Pathol Lab Med . 2021 Oct; 146(7):862-871. PMID: 34619755
Context.—: Minimal residual disease (MRD) is a major prognostic factor in multiple myeloma, although validated technologies are limited. Objective.—: To standardize the performance of the LymphoTrack next-generation sequencing (NGS) assays...
3.
Genetic complexity impacts the clinical outcome of follicular lymphoma patients
Garcia-Alvarez M, Alonso-Alvarez S, Prieto-Conde I, Jimenez C, Sarasquete M, Chillon M, et al.
Blood Cancer J . 2021 Jan; 11(1):11. PMID: 33431798
No abstract available.
4.
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete M, Garcia-Alvarez M, et al.
Blood Cancer J . 2020 Oct; 10(10):108. PMID: 33127891
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation...
5.
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
Medina A, Jimenez C, Sarasquete M, Gonzalez M, Chillon M, Balanzategui A, et al.
Blood Cancer J . 2020 Feb; 10(2):14. PMID: 32029700
Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features...
6.
Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas
Garcia-Alvarez M, Alonso-Alvarez S, Prieto-Conde I, Jimenez C, Sarasquete M, Chillon M, et al.
Blood Cancer J . 2019 Jun; 9(7):52. PMID: 31209206
Follicular lymphoma (FL) is a heterogeneous disease whose pathogenesis remains partially unknown. Around 20% of FL patients experience early progression or treatment-refractory disease and 2-3% of patients per year experience...
7.
HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis
Garcia-Alvarez M, Alcoceba M, Lopez-Parra M, Puig N, Anton A, Balanzategui A, et al.
PLoS One . 2017 Mar; 12(3):e0172978. PMID: 28249016
Introduction: Molecular alterations leading progression of asymptomatic CLL-like high-count monoclonal B lymphocytosis (hiMBL) to chronic lymphocytic leukemia (CLL) remain poorly understood. Recently, genome-wide association studies have found 6p21.3, where the...